My Authors
Read all threads
Presenting the GLOBAL Registrational Results of LIBRETTO-001: A Phase 1/2 Trial of Selpercatinib #LOXO-292 in Patients with #RET + NSCLC !Thank you to all the patients and caregivers ! Huge win for RET + #NSCLC patients #precisionmedicine #LCSM #endcancer Image
RET Fusions are bonafide #lung cancer drivers #LSCM Image
Patient Characteristics on the Primary analysis set Image
Efficacy of #Selpercatinib Primary Analysis Set (n=105) Image
#Selpercatinib Safety Profile Data Image
Efficacy of #Selpercatinib : treatment Naïve Patients. Do we need a randomized trial here ? @JackWestMD @n8pennell @rdoebele @DHymanMD @alexdrilon @VamsiVelcheti @StephenVLiu @bensolomon1 Image
#Selpercatinib demonstrated robust and durable anti-tumor activity in RETfusion-positive #NSCLC Image
Missing some Tweet in this thread? You can try to force a refresh.

Enjoying this thread?

Keep Current with Vivek Subbiah, MD

Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

Twitter may remove this content at anytime, convert it as a PDF, save and print for later use!

Try unrolling a thread yourself!

how to unroll video

1) Follow Thread Reader App on Twitter so you can easily mention us!

2) Go to a Twitter thread (series of Tweets by the same owner) and mention us with a keyword "unroll" @threadreaderapp unroll

You can practice here first or read more on our help page!

Follow Us on Twitter!

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just three indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3.00/month or $30.00/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!